Phases of diabetes

Pediatric Diabetes

Volumn 8, Issue 1, 2007, Pages 44-47

  Couper, Jennifer ^a   Donaghue, Kim ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INSULIN; NICOTINAMIDE; PLACEBO;

ARTICLE; AUTOIMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DELAYED DIAGNOSIS; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIABETOGENESIS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE PREDISPOSITION; EVIDENCE BASED MEDICINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET TRANSPLANTATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMISSION; RISK ASSESSMENT; RISK FACTOR;

CHILD; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PREDIABETIC STATE; REMISSION INDUCTION;

EID: 33847795271     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2006.00225.x     Document Type: Article

References (28)

1. Colman PG, Steele C, Couper JJ et al. Islet autoimmunity in infants with a Type I diabetic relative is common but is frequently restricted to one autoantibody. Diabetologia 2000: 43: 203-209.
2. Kimpimaki T, Kulmala P, Savola K et al. Natural history of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population. J Clin Endocrinol Metab 2002: 87: 4572-4579.
3. Knip M. Natural course of preclinical type 1 diabetes. Horm Res 2002: 57: 6-11.
4. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002: 346: 1685-1691.
5. Bingley PJ, Christie MR, Bonifacio E et al. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 1994: 43: 1304-1310.
6. Verge CF, Gianani R, Kawasaki E et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996: 45: 926-933.
7. A merican D iabetes A ssociation. Prevention of type 1 diabetes mellitus. Diabetes Care 2003: 26: 140.
8. http://www.diabetestrialnet.org. 2006
9. Ginsberg-Fellner F, Witt ME, Fedun B et al. Diabetes mellitus and autoimmunity in patients with the congenital rubella syndrome. Rev Infect Dis 1985: 7 (Suppl. 1): S170-S176.
10. Mcintosh ED, Menser MA. A fifty-year follow-up of congenital rubella. Lancet 1992: 340: 414-415.
11. Hyoty H, Hiltunen M, Knip M et al. A prospective study of the role of coxsackie B and other enterovirus infections in the pathogenesis of IDDM. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes 1995: 44: 652-657.
12. Akerblom HK, Virtanen SM, Ilonen J et al. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: A pilot study. Diabetologia 2005: 48: 829-837.
13. Norris JM, Barriga K, Klingensmith G et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA 2003: 290: 1713-1720.
14. Ziegler AG, Schmid S, Huber D, Hummel M, Bonifacio E. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA 2003: 290: 1721-1728.
15. Filippi C, Von Herrath M. How viral infections affect the autoimmune process leading to type 1 diabetes. Cell Immunol 2005: 233: 125-132.
16. Dahlquist G. Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis. Diabetologia 2006: 49: 20-24.
17. Bober E, Dundar B, Buyukgebiz A. Partial remission phase and metabolic control in type 1 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab 2001: 14: 435-441.
18. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998: 128: 517-523.
19. Keskinen PK. First-phase insulin response in young healthy children at genetic and immunological risk for type I diabetes. Diabetologia 2002: 45: 1639-1648.
20. American Diabetes Association. Type 2 diabetes in children and adolescents. Pediatrics 2000: 105: 671-680.
21. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2003: 26: 21-24.
22. Lombardo F, Valenzise M, Wasniewska M et al. Two-year prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: The key-role of age at diagnosis. Diabetes Nutr Metab Clin Exp 2002: 15: 246-251.
23. De Beaufort CE, Houtzagers CM, Bruining GJ et al. Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: Two-year follow-up of a randomized, prospective trial. Diabet Med 1989: 6: 766-771.
24. Shapiro AM, Lakey JR, Ryan EA et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000: 343: 230-238.
25. Ryan EA, Lakey JR, Paty BW et al. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002: 51: 2148-2157.
26. Shapiro AM, Ricordi C, Hering BJ et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006: 255: 1318-1330.
27. Odorico JS, Sollinger HW. Technical and immunosuppressive advances in transplantation for insulin-dependent diabetes mellitus. World J Surg 2002: 26: 194-211.
28. Gale EA, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): A randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004: 363: 925-931.